课题基金 / 基金详情

B2036 PEG IN ACROMEGALY

B2036 PEG IN ACROMEGALY
B2036 肢端肥大症中的 PEG
批准号：
6264638
负责人：
DAVID L KLEINBERG
金额：
$2.1万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6264638
关键词：
acromegaly biological signal transduction clinical research drug adverse effect drug screening /evaluation endocrine disorder chemotherapy hormone inhibitor hormone receptor human subject human therapy evaluation insulinlike growth factor placebos polyethylene glycols skeletal disorder chemotherapy somatotropin

项目摘要

项目成果

DAVID L KLEINBERG的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This randomized, double-blind, placebo controlled, study of B2036-PEG will attempt to determine the tolerability and efficacy of this drug in the subjects with acromegaly. B2036-PEG is a growth hormone receptor antagonist which will reversibly bind to the growth hormone receptor, blocking signal tranduction, and lead to reductions in circulating IGF-1.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SURGICAL DEBULKING PLUS OCTREOTIDE VERSUS OCTREOTIDE ALONE IN ACROMEGALY
PREVALENCE OF GROWTH HORMONE DEFICIENCY & RANGES OF IGF-1 IN NORMAL ELDERLY
PREVALENCE OF GROWTH HORMONE DEFICIENCY & RANGES OF IGF-1 IN NORMAL ELDERLY
Prevalence of Growth Hormone Deficiency & Ranges of IGF-1 in Normal Elderly
海外基金